Statements in this press release regarding management's future
expectations, beliefs, intentions, goals, strategies, plans or prospects,
including statements relating to the advancement of the belinostat and
CR011- vcMMAE programs and the projected timing for updates on the
CuraGen's clinical trial results may constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements can be identified by terminology such as
"anticipate," "believe," "could," "could increase the likelihood,"
"estimate," "expect," "intend," "is planned," "may," "should," "will,"
"will enable," "would be expected," "look forward," "may provide," "would"
or similar terms, variations of such terms or the negative of those terms.
Such forward-looking statements involve known and unknown risks,
uncertainties and other factors including the risk that any one or more of
CuraGen's drug development programs will not proceed as planned for
technical, scientific or commercial reasons or due to patient enrollment
issues or based on new information from nonclinical or clinical studies or
from other sources, the success of competing products and technologies,
CuraGen's stage of development as a biopharmaceutical company, government
regulation and healthcare reform, technological uncertainty and product
development risks, product liability exposure, uncertainty of additional
funding, CuraGen's history of incurring losses and the uncertainty of
achieving profitability, reliance on research collaborations and strategic
alliances, competition, patent infringement claims against CuraGen's
products, processes and technologies, CuraGen's ability to protect its
patents and proprietary rights and uncertainties relating to
commercialization rights, as well as those risks, uncertainties and factors
referred to in the Company's Quarterly Report on Form 10-Q for the quarter
|SOURCE CuraGen Corporation|
Copyright©2007 PR Newswire.
All rights reserved